🔍

TAKE - Take Solutions

📊 NSE: TAKE 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 14:06

📢 Recent Corporate Announcements

Take Solutions Enters Longevity & Anti-Ageing Market Targeting $67B Global Opportunity

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 17 Apr 2026, 10:37 AM

Take Solutions has announced a strategic entry into the longevity and anti-ageing sector, leveraging its clinical research and life sciences expertise. The company aims to capture a share of the global longevity market, projected to reach $67.03 billion by 2035 with a 9.41% CAGR. In India, the anti-aging supplements market is expected to grow from $168.6 million in 2025 to $341.4 million by 2033. The strategy includes developing science-backed nutraceuticals and digital biohacking tools to diversify revenue streams.

Targeting global longevity market valued at $27.61 billion in 2025, growing at 9.41% CAGR
Focus on India's anti-aging supplements market, projected to reach $341.4 million by 2033
India's anti-aging services market expected to grow to $1,059.6 million by 2035
Strategy involves a dual model of nutraceutical products and predictive digital health tools
Leveraging existing regulatory and clinical research capabilities to ensure product credibility

💡 Investors should monitor the execution timeline for product launches and the impact on margins, as this represents a shift toward consumer-facing healthcare. The stock may see positive sentiment due to the high-growth nature of the longevity and biohacking sectors.

TAKE Solutions Appoints New Statutory Auditors Following Resignation of Previous Firm

🔵 WATCH ⭐ 7/10

REGULATORY 📅 26 Mar 2026, 07:27 PM

TAKE Solutions Limited has appointed M/s. A. Raghavendra Rao & Associates as Statutory Auditors to fill a casual vacancy. This follows the resignation of the previous auditors, M/s. Venkat and Rangaa LLP, effective March 26, 2026. The new firm brings nearly 40 years of experience in audit, taxation, and advisory services across multiple sectors including IT and healthcare. The appointment is subject to shareholder approval as per SEBI regulations.

Appointment of M/s. A. Raghavendra Rao & Associates as Statutory Auditors effective March 26, 2026.
The change follows the resignation of the outgoing auditor, M/s. Venkat and Rangaa LLP.
The new auditing firm was established in 1986 and has nearly 40 years of experience in corporate and government audits.
The Board meeting approving the appointment was held on March 26, 2026, between 06:30 PM and 07:00 PM.

💡 Investors should monitor for the specific reasons behind the previous auditor's resignation to ensure there are no governance or accounting red flags. Maintain a cautious stance until the next audited financial results are published under the new firm.

Take Solutions Appoints New Statutory Auditor Following Resignation of Previous Firm

🔵 WATCH ⭐ 6/10

BOARD_MEETING 📅 26 Mar 2026, 07:16 PM

Take Solutions Limited has appointed M/s. A. Raghavendra Rao & Associates as its new Statutory Auditor effective March 26, 2026. This appointment fills a casual vacancy created by the resignation of the previous auditor, M/s. Venkat and Rangaa LLP. The new auditing firm, established in 1986, brings nearly 40 years of experience in audit and assurance across sectors like IT, healthcare, and banking. The transition is subject to shareholder approval as per SEBI listing regulations.

Appointment of M/s. A. Raghavendra Rao & Associates (FRN: 003324S) as Statutory Auditors effective March 26, 2026.
The change follows the resignation of the previous auditing firm, M/s. Venkat and Rangaa LLP.
The new firm has nearly 40 years of professional experience in statutory, tax, and internal audits since its establishment in 1986.
The Board meeting to approve the appointment was conducted between 06:30 PM and 07:00 PM on March 26, 2026.

💡 Investors should monitor for the specific reasons behind the previous auditor's resignation to ensure there are no underlying accounting or governance concerns. A change in auditors mid-term usually warrants a cautious approach until the first set of financials from the new auditor is released.

Statutory Auditor Venkat and Rangaa LLP Resigns from Take Solutions Due to Fee Constraints

🔵 WATCH ⭐ 7/10

MANAGEMENT 📅 25 Mar 2026, 05:58 PM

Take Solutions Limited has announced the resignation of its statutory auditor, M/s. Venkat and Rangaa LLP, effective March 25, 2026. The auditor cited that the audit fees were not commensurate with the size and complexity of the business and the reporting requirements. Notably, the auditor resigned just 50 days after their appointment on February 3, 2026. The firm had recently submitted the Limited Review Report for the quarter ended December 2025 on February 14, 2026.

M/s. Venkat and Rangaa LLP resigned as Statutory Auditor effective March 25, 2026.
The auditor was appointed on February 3, 2026, resulting in an exceptionally short tenure of less than two months.
Reason for resignation: Audit remuneration was deemed insufficient relative to the company's business complexity and statutory scope.
The auditor confirmed there are no other material reasons for the resignation beyond the fee constraints.

💡 Investors should exercise caution as frequent or sudden auditor changes can sometimes signal underlying governance or financial reporting disagreements. Monitor the company's next appointment and the transition process closely.

Take Solutions to Close Trading Window from April 1, 2026, for FY26 Results

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Mar 2026, 05:24 PM

Take Solutions Limited has announced the closure of its trading window effective April 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. This closure is in anticipation of the audited financial results for the quarter and full year ending March 31, 2026. The restriction applies to all promoters, directors, and designated persons, preventing them from dealing in company securities. The window will remain closed until 48 hours after the financial results are officially declared to the exchanges.

Trading window closure begins on April 1, 2026, for the quarter and year ending March 31, 2026.
Applies to all Promoters, Directors, Key Management Personnel, and Designated Persons.
Window will reopen 48 hours after the declaration of the audited financial results.
The board meeting date for result approval will be announced separately in due course.

💡 This is a routine regulatory filing and does not impact the company's fundamentals. Investors should monitor for the upcoming board meeting date to review the audited FY26 performance.

TAKE Solutions Launches Take.Health AI Platform Targeting $197B Healthcare Market

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 25 Mar 2026, 10:09 AM

TAKE Solutions has launched Take.Health, an AI-driven digital health companion designed to capitalize on India's $197 billion preventive healthcare opportunity. The platform utilizes an asset-light, subscription-based model to provide personalized health insights, lab report analysis, and chronic condition tracking for retail and enterprise segments. This strategic move aims to create recurring revenue streams by leveraging India's base of over 600 million smartphone users. The initiative marks a significant pivot for the company into the high-growth digital health and AI analytics space.

Targets India's preventive healthcare market projected to reach $197 billion by 2030.
Platform features AI-powered lab analysis, predictive risk identification, and condition-specific tracking for diabetes and hypertension.
Business model focuses on scalable, recurring revenue through subscriptions and data-led services.
Leverages India's digital adoption base of over 600 million smartphone users for rapid scaling.
Positions the company to participate in the broader $370 billion Indian healthcare sector through a technology-first approach.

💡 Investors should monitor user adoption metrics and subscription growth for Take.Health as it represents a high-margin digital pivot. Watch for partnership announcements with diagnostics and insurance providers which could further validate the platform's ecosystem value.

TAKE Solutions Incorporates Wholly Owned Subsidiary TAKE VENTURES PRIVATE LIMITED

🟡 NEUTRAL ⭐ 4/10

EXPANSION 📅 11 Mar 2026, 06:07 PM

TAKE Solutions Limited has announced the incorporation of a new wholly-owned subsidiary named TAKE VENTURES PRIVATE LIMITED on March 11, 2026. The subsidiary has been established with an authorized share capital of ₹25,00,000, divided into 2,50,000 equity shares of ₹10 each. This new entity will focus on software development, IT consultancy, and technology-enabled solutions to drive the company's growth strategy. The parent company holds 100% control through cash subscription of the initial share capital.

Incorporated TAKE VENTURES PRIVATE LIMITED as a 100% wholly-owned subsidiary on March 11, 2026
Authorized share capital of ₹25,00,000 consisting of 2,50,000 equity shares of ₹10 each
Subsidiary to operate in the IT industry focusing on software design, development, and consultancy
The move is intended to support the company's long-term growth and expansion in the technology sector

💡 Investors should view this as a routine corporate expansion and monitor how this new entity contributes to the company's consolidated IT services revenue in future quarters.

TAKE Solutions Approves Shifting Registered Office and Appoints New Statutory Auditors

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 07 Mar 2026, 06:42 PM

TAKE Solutions held an Extraordinary General Meeting (EOGM) on March 7, 2026, to approve several key governance and strategic changes. Shareholders voted to regularize the appointments of two Non-Executive Directors and approved M/s. Venkat and Rangaa LLP as the new Statutory Auditors following a casual vacancy. A significant special resolution was passed to shift the company's Registered Office from Tamil Nadu to Maharashtra. These moves coincide with the company's stated strategic transformation toward AI-driven healthcare and scalable technology platforms.

Approved the appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following the resignation of M/s. Sundar Srini & Sridhar.
Passed a special resolution to shift the Registered Office from Tamil Nadu to Maharashtra.
Regularized the appointments of Mr. Parmeshvar Dhangare and Mr. Vilas Munis as Non-Executive Directors.
Company reported a total of 66,526 members as of the February 28, 2026, cut-off date.
Management highlighted a strategic pivot toward AI-driven healthcare, diagnostics, and preventive care.

💡 Investors should monitor the transition to the new statutory auditors and the relocation to Maharashtra for any operational disruptions. The strategic shift toward AI-driven healthcare is a long-term play that requires tracking for actual revenue execution.

TAKE Solutions EOGM: Shifting Office to Maharashtra and New Auditor Appointment

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 07 Mar 2026, 06:38 PM

TAKE Solutions held an Extra Ordinary General Meeting on March 7, 2026, to approve several key governance and operational changes. Shareholders voted on the regularization of two Non-Executive Directors and the appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following a casual vacancy. A significant special resolution was proposed to shift the company's registered office from Tamil Nadu to Maharashtra. The management also emphasized a strategic pivot toward AI-driven healthcare and diagnostics platforms.

Approval for shifting the Registered Office from Tamil Nadu to Maharashtra via a Special Resolution.
Appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors to fill the vacancy caused by the resignation of M/s. Sundar Srini & Sridhar.
Regularization of Mr. Parmeshvar Dhangare and Mr. Vilas Munis as Non-Executive Non-Independent Directors.
The meeting was attended by 38 members out of a total shareholder base of 66,526 as of February 28, 2026.
Strategic focus reaffirmed on building scalable technology-led platforms in AI-driven healthcare and preventive care.

💡 Investors should monitor the transition to the new registered office and any further disclosures regarding the auditor's resignation. The company's shift toward AI-driven healthcare is a long-term strategic move that requires tracking for execution milestones.

TAKE Solutions Integrates Anthropic's Claude AI to Target $370B Healthcare Sector

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 21 Feb 2026, 03:12 PM

TAKE Solutions has announced a strategic integration of Anthropic’s Claude AI to enhance its healthcare technology stack. This move specifically targets the $370 billion healthcare sector by powering platforms like the 'One Minute Clinic' and a 'Unified AI Marketplace'. The initiative focuses on transitioning from reactive treatment to predictive and preventive care models using advanced clinical decision intelligence. By leveraging these AI capabilities, the company aims to improve operational efficiency and scale its services for global healthcare networks and pharmaceutical companies.

Strategic integration of Anthropic's Claude AI to drive dominance in the $370B global healthcare market.
Enhancement of the 'One Minute Clinic' initiative for rapid health assessments and intelligent report generation.
Development of a Unified AI Marketplace for hospitals, diagnostic centers, and pharmaceutical providers.
Focus on predictive healthcare management to identify early health risks and enable proactive care.

💡 Investors should view this as a significant technological upgrade that positions the company in the high-growth AI-healthcare segment. Monitor the company's upcoming quarterly results for signs of revenue traction from these newly enhanced AI platforms.

Take Solutions Sets Feb 28 as Cut-off Date for EOGM Scheduled on March 7, 2026

🟡 NEUTRAL ⭐ 4/10

BOARD_MEETING 📅 18 Feb 2026, 03:10 PM

Take Solutions Limited has announced an Extra Ordinary General Meeting (EOGM) to be held on March 7, 2026, via video conferencing. The company has established February 28, 2026, as the cut-off date to determine shareholder eligibility for participating in the remote e-voting process. The e-voting period is scheduled to run from March 4, 2026, starting at 9:00 a.m., until March 6, 2026, ending at 5:00 p.m. This meeting is a regulatory requirement to seek shareholder approval for specific corporate resolutions.

Extra Ordinary General Meeting (EOGM) scheduled for March 7, 2026, at 12:00 p.m. IST
Cut-off date for e-voting eligibility is fixed as February 28, 2026
Remote e-voting window opens on March 4 and closes on March 6, 2026
Meeting to be conducted virtually through Video Conferencing (VC) or Other Audio-Visual Means

💡 Investors should monitor for the full EOGM notice to understand the specific resolutions being voted upon. Shareholders interested in exercising their voting rights must ensure they hold the stock by the February 28 cut-off date.

TAKE Solutions to Build Unified AI Platform for $370B Healthcare Ecosystem

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 17 Feb 2026, 10:25 AM

TAKE Solutions has announced a strategic initiative to develop a Scalable Unified AI Platform, targeting India's $370 billion healthcare sector and a $197 billion preventive healthcare opportunity. The platform will act as a digital infrastructure layer and marketplace, enabling hospitals and labs to deploy AI for diagnostics, clinical trials, and hospital workflows. This move aligns with the IndiaAI Mission and positions the company to capture growth in the global AI healthcare market, which is projected to exceed $180 billion by 2030. The initiative marks a significant pivot toward high-growth digital health infrastructure.

Developing a Unified AI Platform to address the $370 billion Indian healthcare ecosystem.
Targeting a $197 billion preventive healthcare opportunity through democratized AI access.
Platform to serve as a Healthcare AI Marketplace for diagnostics, clinical trials, and hospital workflows.
Strategic alignment with the IndiaAI Mission and the global AI healthcare market projected to surpass $180 billion by 2030.

💡 Investors should monitor the company's ability to onboard healthcare providers and the subsequent impact on revenue growth from this digital platform. While the strategic direction is positive, execution and monetization within the competitive AI space will be critical factors to watch.

Take Solutions Reports Q3 Profit of ₹1.11 Cr; Auditors Raise Going Concern Doubts

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 14 Feb 2026, 10:36 PM

Take Solutions reported a standalone net profit of ₹110.96 Lakhs for Q3 FY26, though this was driven entirely by other income as revenue from operations remained at zero. The company's auditors have issued a qualified opinion, highlighting material uncertainty regarding the firm's ability to continue as a going concern due to significant past losses and unpaid statutory dues. Management is currently exploring non-cash M&A opportunities to diversify operations following the divestment of its major subsidiary. Additionally, the board has rejected a promoter's request for reclassification to the public category citing procedural gaps.

Revenue from operations stood at ₹0.00 for the quarter, with total income of ₹146.14 Lakhs derived from other sources.
Auditors flagged ₹883.2 Lakhs in tax assets and ₹516.4 Lakhs in indirect tax credits with uncertain recoverability.
Company faces contingent liabilities of ₹1,080.3 Lakhs related to direct tax litigations pending before various forums.
Net worth remains significantly impacted by a ₹6,973.60 Lakhs loss in the previous financial year following the Ecron Acunova divestment.
The Board declined Mr. Srinivasan HR's request to move from 'Promoter' to 'Public' category due to pending procedural requirements.

💡 Investors should remain highly cautious as the auditor's 'going concern' warning and lack of operational revenue indicate extreme financial risk. The stock is speculative until the company successfully executes its proposed M&A strategy or restarts core business operations.

Take Solutions to Hold EOGM for Auditor Appointment and Office Shift to Maharashtra

🔵 WATCH ⭐ 6/10

MANAGEMENT 📅 13 Feb 2026, 07:50 PM

Take Solutions Limited has scheduled an Extraordinary General Meeting (EOGM) for March 07, 2026, to seek shareholder approval for several significant corporate changes. Key resolutions include the appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following the resignation of the previous auditors. The company also proposes shifting its registered office from Tamil Nadu to Maharashtra, which requires a special resolution. Additionally, shareholders will vote on the regularization of two Non-Executive Directors, Mr. Parmeshvar Dhangare and Mr. Vilas Munis.

EOGM scheduled for March 07, 2026, to be held via Video Conferencing/Other Audio-Visual Means.
Proposed appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors to fill a casual vacancy.
Special resolution to shift the Registered Office from Chennai, Tamil Nadu, to the State of Maharashtra.
Regularization of Mr. Parmeshvar Dhangare and Mr. Vilas Munis as Non-Executive Non-Independent Directors.
Remote e-voting period is set from March 04 to March 06, 2026, with a cut-off date of February 28, 2026.

💡 Investors should monitor the rationale behind the auditor's resignation and the strategic purpose of shifting the registered office to Maharashtra. Shareholders eligible as of February 28, 2026, should participate in the e-voting process to voice their stance on these governance changes.

Take Solutions to Shift Office to Maharashtra, Appoints New Auditor and Reviews Promoter Exit

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 11 Feb 2026, 06:51 PM

Take Solutions has announced a major structural shift, moving its registered office from Tamil Nadu to Maharashtra. The board has appointed M/s. Venkat and Rangaa LLP as the new Statutory Auditor to fill a casual vacancy following the previous auditor's resignation. Crucially, the board is reviewing a request from promoter Mr. Srinivasan H R to be reclassified as a public shareholder, with a follow-up meeting scheduled for February 14, 2026. Additionally, the company is progressing with an AI-driven Diagnostic & Preventive Health Care Platform as part of its long-term strategy.

Proposed shifting of registered office from Tamil Nadu to Maharashtra subject to shareholder approval.
Appointment of M/s. Venkat and Rangaa LLP as Statutory Auditors following the resignation of M/s Sundar Srini & Sridhar.
Promoter Mr. Srinivasan H R has formally requested reclassification from 'Promoter' to 'Public' category.
Extra Ordinary General Meeting (EOGM) scheduled for March 7, 2026, for member approvals.
Board reviewed progress on an advanced AI-driven Diagnostic & Preventive Health Care Platform.

💡 Investors should closely monitor the February 14 board meeting regarding the promoter's reclassification request, as this often signals a change in management control or potential exit. The change in statutory auditors also necessitates a review of the company's recent financial disclosures for any underlying issues.

View All TAKE Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Life Sciences (LS) segment witnessed a de-growth of 64.35% in FY21. Supply Chain Management (SCM) segment witnessed a de-growth of 75.43% in FY21.

Geographic Revenue Split

High dependence on the US market (specific percentage not provided).

Profitability Margins

EBITDA margin was almost 19% in the last quarter (Q1 FY22). The company expects to stabilize at 19-20% EBITDA margins once a certain revenue run rate is hit.

EBITDA Margin

EBITDA margin was approximately 19% in the most recent quarter, with a target to stabilize at 19-20%.

Capital Expenditure

Not explicitly disclosed in the provided text, though 'Purchase of Property Plant and Equipment' is mentioned in the cash flow statement without a specific total value for the period.

Credit Rating & Borrowing

The company has about Rs. 500 crores in debt. Specific interest rate percentage is not mentioned, but liquidity is described as 'strained'.

⚙️ Operational Drivers

Raw Materials

Pass-through expenses (costs from sponsors given to sites in clinical trials).

Capacity Expansion

Not explicitly stated in units, but the company aims to scale up the business with the help of HIG.

Raw Material Costs

Cost of revenue includes pass-through expenses; specific percentage of revenue not provided.

Manufacturing Efficiency

Not applicable (service-based), but 'burning' of orders was constrained by COVID-19.

📈 Strategic Growth

Expected Growth Rate

19-20%

Growth Strategy

Strategic partnership with HIG to grow the Navitas brand; deleveraging to become a zero-debt company; diversification into related areas; and improving cash profitability.

Products & Services

Clinical trials, Life Sciences services, Supply Chain Management (exited in FY21).

Brand Portfolio

Navitas, APA Engineering (exited).

New Products/Services

Related areas of diversification not in conflict with the Navitas brand.

Market Expansion

Focus on the United States market to create value for the Navitas business.

Market Share & Ranking

Relatively small size of operations in a highly competitive industry.

Strategic Alliances

Strategic partnership with HIG (H.I.G. Capital).

🌍 External Factors

Industry Trends

Changing dynamics of the global pharma industry; shift towards Life Sciences (96% of revenue in FY21).

Competitive Landscape

Highly competitive industry with a relatively small size of operations.

Competitive Moat

Strategic partnership with HIG, which has a track record of creating shareholder value; the Navitas brand.

Macro Economic Sensitivity

Socio-economic conditions arising from the COVID-19 pandemic.

Consumer Behavior

Impacted by the COVID-19 pandemic and changing dynamics in the pharma industry.

Geopolitical Risks

Not explicitly mentioned, but fortunes are linked to the global pharma industry.

⚖️ Regulatory & Governance

Industry Regulations

Compliance with Indian Accounting Standards (Ind AS), specifically Ind AS 37 regarding provisions and contingent liabilities.

Taxation Policy Impact

Qualified opinion regarding internal financial controls over assessment of impairment in carrying value of tax assets and direct tax litigations.

Legal Contingencies

Pending direct tax litigations before various forums for various assessment years; impact of pending litigations as of March 31, 2025, disclosed in Note No. 4.